The company has exclusive license to the proprietary Notch-mediated stem cell expansion and directed differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and multiple clinical trials.

Our innovative and well-established platform can be used to generate a range of unmodified and modified (engineered) progenitor and immune cells to boost the patient’s blood and immune system to eliminate cancer and virally infected cells.

Deverra’s team includes pioneers who were the first to demonstrate clinical effectiveness using expanded stem cell therapies and  non-HLA matched, off-the-shelf universal donor cell therapies.